<DOC>
	<DOCNO>NCT01709370</DOCNO>
	<brief_summary>This phase II study evaluate efficacy safety pre-operative use letrozole plus PD 0332991 ( combination therapy )</brief_summary>
	<brief_title>Letrozole CDK 4/6 Inhibitor ER Positive , HER2 Negative Breast Cancer Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman Primary tumor great 2 cm diameter Histologically proven invasive breast cancer Positive estrogen receptor Negative HER2 receptor ECOG performance status ≤ 1 Karnofsky performance status ≥ 70 % Laboratory value must follow : Absolute neutrophil count ≥ 1,500/mm3 ; Platelets ≥ 100,000/mm3 ; Hemoglobin ≥ 9 g/dL ; Bilirubin ≤ 1.5 × institutional upper limit normal ( ULN ) ; Serum Creatinine ≤ 1.5 × ULN ; Alkaline phosphatase ≤ 2 × ULN ; AST ALT ≤ 2 × ULN ; Normal find ECG QTc ≤ 470 msec ( base mean value triplicate ECGs ) ; Left ventricular ejection fraction ( LVEF ) ≥ 60 % . Able give write informed consent form Able follow prescription instruction reasonably well Male Severe psychiatric disorder Prior history malignancy within 5 year study entry , aside basal cell carcinoma skin carcinomainsitu uterine cervix Locally advance breast cancer ( T3N1 Any T4 Any N2 , N3 ) , distant metastasis Multifocal multicentric breast cancer except large lesion great 2cm Major surgery within 3 week first study treatment Current use anticipate need : Food drug know strong CYP3A4 inhibitor ; drug know strong CYP3A4 inducer Severe cardiovascular disease previous 6 month Active inflammatory bowel disease chronic diarrhea Renal Impairment Poor adrenal function Hepatitis B and/or hepatitis C carrier ( unless normal hepatic function ) Known human immunodeficiency virus infection Known hypersensitivity antiaromatase drug cell cycle inhibitor Other severe acute chronic medical psychiatric condition , laboratory abnormality would impart , judgment investigator , excess risk associate study participation study drug administration , , judgment investigator , would make patient inappropriate entry study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>